BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Elan Corporation PLC (ELN) to Sell Remaining 7.75 Million Shares of Alkermes plc (ALKS)


2/1/2013 6:52:18 AM

DUBLIN--(BUSINESS WIRE)-- Elan Corporation, plc (“Elan”) (ELN) announced that, following the close of trading today, Elan, through its wholly-owned subsidiary, Elan Science Three Limited, agreed to sell, on customary terms, all of its remaining 7,750,000 ordinary shares of Alkermes plc (“Alkermes”) (ALKS) through Jefferies & Company, Inc. pursuant to Rule 144 under the U.S. Securities Act of 1933. The sale is expected to close on February 6, 2013.

In September 2011, upon the combination of Elan’s Drug Technology (EDT) business with Alkermes, Inc., Elan received 31,900,000 ordinary shares in the newly created Alkermes. In March 2012, Elan sold 24,150,000 ordinary shares of Alkermes in an underwritten public offering. After the closing, Elan will no longer own any ordinary shares of Alkermes.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.

Contact:

Elan Corporation, plc

Investor Relations

Chris Burns, 800-252-3526

David Marshall, + 353-1-709-4444

or

Media Relations

Emer Reynolds, + 353-1-709-4022

Jonathan Birt, +44-751-559-7858


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->